As part of PPD, Evidera serves life science organizations to optimize product value through the generation, analysis, and communication of evidence by:
Developing, capturing, and effectively communicating the required health outcomes and economic evidence
Bringing world-class science, methodological expertise, and thought leadership to everything we do
We have worked with nearly all of the top biopharma, medical device, and diagnostic manufacturers, and we are a preferred provider for most of the top 50 biopharma companies. Evidera’s 400+ scientists and consultants work closely with their clients to ensure that their evidence needs are met. We have more than 1,100 research studies in progress with our clients in most major therapeutic areas.
In Serving Our Clients, We Partner With
The hope of 21st century healthcare is to become more patient-centric, with patients as active participants in their care and services designed in partnership with patients to incorporate and embrace patient needs and preferences. Evidera provides an opportunity for our patient partners (patients and/or their caregivers) to go beyond the role of research subjects to become actively engaged partners throughout the research process.
Evidera’s researchers are leaders in professional societies and academic working groups focused on developing best practices for engaging patient partners effectively in the research process. With a long history of established research partnerships with advocacy organizations in a variety of therapeutic areas, Evidera has worked directly with foundations on numerous research projects, including developing and validating patient-reported, observer-reported, performance, and clinician-reported outcome tools. Evidera is now working directly with these organizations and individual patients to expand their role in the research process in innovative ways. Read more about our Patient-Centered Research here.
Evidera works closely with regulators, payers, and health technology assessment authorities throughout North America and Europe. We have formed one of the largest payer networks in the industry comprising more than 2,000 payers in key markets and 300 payers in emerging markets. We leverage our relationships to help our clients understand the value and market access decision drivers and to understand how product attributes and evidence plans enhance or limit value and price potential. We work with payers across varying levels, and our relationships with these important stakeholders ensure our clients have the insight necessary to develop solid access strategies across the product life cycle.
National level (e.g., NICE, Transparency Commission, German Federal Joint Committee, Centers for Medicare & Medicaid Services, Ministries of Health, pricing committees)
Regional level (e.g., health plans, sickness funds, regional HTA, hospital commissioning groups)
Local level (e.g., hospitals, clinical commissioning groups, physicians)
Healthcare providers are pivotal to innovation in healthcare technologies — participating in scientific research, clinical development, and evaluation of the value and role in the treatment of novel therapies. Evidera partners with clinicians in the design of new outcomes measures, the definition and execution of observational studies, and consultation on value drivers and evidence requirements for new treatments. In collaboration with clinical experts, Evidera scientists and consultants work to define, develop, and communicate the evidence that will optimally realize the value of therapeutic advances.